All News

takayasu.jpg

Diagnosing and Managing GCA and Takayasu’s Arteritis

Adela Castro, MD

Giant-cell arteritis and Takayasu’s arteritis are both large-vessel vasculitides, but each brings its own diagnostic and management challenges. Many of the difficulties overlap because they are rare, heterogeneous, and lack perfect diagnostic tests or specific biomarkers.

Read Article
Cockerell

Vasculitis

Richard Conway, MBBChBAO, PhD

Sunday’s vasculitis session at RNL26 was a fantastic update on inflamed blood vessels, large and small, by two experts in the field: rheumatologist Dr. Mike Putman and dermatopathologist Dr. Clay Cockerell.

Read Article
RheumNow Podcast square

ANA Pollution (2.06.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com

Read Article
patient.safety.jpg

FDA vs. Amgen: At Odds Over Avacopan

MedPage Today

The FDA has requested that Amgen voluntarily withdraw avacopan (Tavneos), a treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but the company said it has no plans to pull the drug from the market.

Read Article
artangiogca.jpg

Giant Cell Arteritis Outcomes in Canada

Jack Cush, MD

A retrospective cohort study of patients with giant cell arteritis (GCA) demonstrates relapses are common and seen in nearly half of patients, were common after treatment is stopped and is not effectively averted by methotrexate (MTX).

Read Article
Aorta

Aortitis in Giant Cell Arteritis Treated with Tocilizumab

Jack Cush, MD

The The Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group studied giant cell arteritis with aortitis, comparing the efficacy of intravenous vs. subcutaneously (SC) tocilizumab (TCZ) - demonstrating the superiority of SC TCZ.

Read Article
RheumNow Podcast square

Emergencies, Independence & Hemorrhage (1.23.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com

Read Article
GCA.glossary.wordle

Best of 2025: Glossary for Giant Cell Arteritis

Jack Cush, MD

Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving international experts.

Read Article
Vexas

Best of 2025: Overview of the VEXAS Syndrome

Jack Cush, MD

A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome.

Read Article
RheumNow Podcast square

Reefer Madness (12.12.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal and regulatory reports from this past week on RheumNow.com.  B cell drugs in SLE and ITP, biomarkers in GCA & PSS and great videos by APPs.

Read Article
Diagnosing and Managing GCA and Takayasu’s Arteritis Giant-cell arteritis (GCA) and Takayasu’s arteritis (TAK) are both large-vessel vasculitides, but each brings its own diagnostic and management challenges. Many of the difficulties overlap because they are rare, https://t.co/ePJqcMjcBA
Dr. John Cush RheumNow ( View Tweet)
What did you miss at RheumNow Live 2026? Our Poster Hall features new data across: • Psoriatic Arthritis • Systemic Lupus Erythematosus • Lupus Nephritis • Vasculitis • Polymyalgia Rheumatica • Axial Spondyloarthritis From Phase III trials to real-world evidence, these

Dr. John Cush RheumNow ( View Tweet)

The vasculitis session at #RNL26 was a fantastic update on inflamed blood vessels, large and small, by two experts in the field. https://t.co/KuVei8jiFu https://t.co/PR4h2qniEL

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA vs. Amgen: At Odds Over Avacopan The FDA has requested that Amgen voluntarily withdraw avacopan (Tavneos), a treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but the company said it has no plans to pull the drug from the market. https://t.co/v5AYm6r53W
Dr. John Cush RheumNow ( View Tweet)
NEJM: Aortitis Due to Large-Vessel Vasculitis 63yoM w/ Hx HTN c/o 3 mos of CP, palpitations, abdominal pain. ESR-104, CRP 85 mg/L. CT showed thickening of the thoracic & abdominal aorta. After 6wks Rx w/ AZA, HCQ, Pred, ESR/CRP still high and pt stared on SC TCZ w/ improvement. https://t.co/1TBreptAFr
Dr. John Cush RheumNow ( View Tweet)
Giant Cell Arteritis Outcomes in Canada A retrospective cohort study of patients with giant cell arteritis (GCA) demonstrates relapses are common and seen in nearly half of patients, were common after treatment is stopped and is not effectively averted by methotrexate (MTX). https://t.co/7hIpn6CJXg
Dr. John Cush RheumNow ( View Tweet)
This week’s RheumNow Live pre-Learn spotlight: Vasculitis & Autoimmune disease. We’re diving into this important topic with expert-led talks from Drs. Nancy Olsen, Matthew Baker, and Clay Cockerell. To help you get the most out of their sessions, our speakers have shared key https://t.co/zLKY52Fi17
Dr. John Cush RheumNow ( View Tweet)
Retrospective single center --103 EGPA pts finds 36 (35%) w/ cardiac involvement, having cardiac Sxs & biomarkers. Most common: pericarditis (77%), cardiomyopathy w/ CHF (55%), myocarditis (36%), cardiogenic shock (14%), cardiac arrest (6%), coronary v.asospasm (8%) https://t.co/JNdVNlVWvA
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: Glossary for Giant Cell Arteritis Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving https://t.co/yfJXZx5r6G
Dr. John Cush RheumNow ( View Tweet)
RNL 25 Replay: Vasculitis Enjoy these excerpts from the RNL 2025 meeting, and join us for RNL 2026 in Dallas, TX - registration is now open! Visit https://t.co/o78Pc8LPsQ for complete details. Featured in this video are excerpts from the following: - Dr. Michael Wechsler: https://t.co/Rk7sBosL72

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×